Rosiglitazone, PPARgamma agonist (ab120762)
Key features and details
- Selective PPARγ agonist
- CAS Number: 122320-73-4
- Purity: > 99%
- Soluble in DMSO to 100 mM and in ethanol to 100 mM (with warming)
- Form / State: Solid
- Source: Synthetic
製品の概要
-
製品名
Rosiglitazone, PPARgamma agonist -
製品の詳細
Selective PPARγ agonist -
生理活性の詳細
Selective PPARγ agonist (EC50 = 43 nM). Thiazolidinedione. Mediates adipocyte differentiation, increases lipogenesis and enhances fatty acid and glucose uptake. Promotes differentiation of urothelial organoids; potent and selective PPARγ agonist.
-
精製度
> 99% -
CAS 番号
122320-73-4 -
構造式
製品の特性
-
体系名
5-[[4- [2- (Methyl- 2- pyridinylamino) ethoxy] phenyl] methyl] - 2,4- thiazolidinedione -
分子量
357.43 -
分子式
C18H19N3O3S -
PubChem 登録番号
77999 -
保存方法
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 100 mM and in ethanol to 100 mM (with warming) -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3 -
由来
Synthetic
-
研究分野
関連製品
-
Related Products
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120762の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab120762, Rosiglitazone, PPARgamma agonist
-
ab3580 staining glucocorticoid receptor in serum starved HeLa cells treated with rosiglitazone (120762), by ICC/IF. Changes in localization of glucocorticoid receptor (translocation from cytoplasm to nucleous) correlates with increased concentration of rosiglitazone, as described in literature.
The cells were incubated at 37°C for 1h in media containing different concentrations of ab120762 (rosiglitazone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab3580 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (8)
ab120762 は 8 報の論文で使用されています。
- Antoine A et al. Dysregulation of the Amniotic PPAR? Pathway by Phthalates: Modulation of the Anti-Inflammatory Activity of PPAR? in Human Fetal Membranes. Life (Basel) 12:N/A (2022). PubMed: 35455039
- Fu J et al. Rosiglitazone Alleviates Mechanical Allodynia of Rats with Bone Cancer Pain through the Activation of PPAR-? to Inhibit the NF-?B/NLRP3 Inflammatory Axis in Spinal Cord Neurons. PPAR Res 2021:6086265 (2021). PubMed: 34484316
- Gantov M et al. Beige adipocytes contribute to breast cancer progression. Oncol Rep 45:317-328 (2021). PubMed: 33416183
- Katoh-Fukui Y et al. Mouse polycomb group gene Cbx2 promotes osteoblastic but suppresses adipogenic differentiation in postnatal long bones. Bone 120:219-231 (2019). PubMed: 30389610
- Wu YX et al. Iguratimod prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator-activated receptor-?. Mol Med Rep 16:8200-8208 (2017). PubMed: 28983607
- Chen X et al. Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs. BMC Musculoskelet Disord 18:423 (2017). PubMed: 29073887
- Pinkosky SL et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 7:13457 (2016). PubMed: 27892461
- Asimakopoulou A et al. Lipocalin-2 (LCN2) regulates PLIN5 expression and intracellular lipid droplet formation in the liver. Biochim Biophys Acta 1842:1513-24 (2014). PubMed: 25086218